Thinking of joining a study?

Register your interest

Become a volunteer?

Clinical trials for Cancer in United States

7243 results

Sort By:

GENOCARE: a Prospective, Randomized Clinical Trial of Genotype-Guided Dosing Versus Usual Care

Study ID: NCT05391126
Start Date: 2022-09-28
End Date: 2027-05
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

178

Intervention / Treatment

Irinotecan

Sponsor

Reema A. Patel

Source: clinicaltrials.gov

Share:
Add to list

Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma

Study ID: NCT04199026
Start Date: 2025-02-25
End Date: 2025-12-31
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

20

Intervention / Treatment

Doxorubicin

Doxorubicin Hydrochloride

Drug Delivery Microdevice

Everolimus

Ganitumab

Ifosfamide

Irinotecan

On the feopanib

Polyethylene Glycol

Temozolomide

Tmsirolimus

Therapeutic Conventional Surgery

Vincristine

Sponsor

M.D. Anderson Cancer Center

Source: clinicaltrials.gov

Share:
Add to list

Targeted Therapy With CDK4/6 Inhibitors in Chemo-Refractory, Rb Wild-Type Extensive SCLC

Study ID: NCT04010357
Start Date: 2020-01-13
End Date: 2025-12
Study Type

Interventional

Study Phase

Phase2

No. of Participants

29

Intervention / Treatment

Abemaciclib,

Sponsor

Case Comprehensive Cancer Center

Source: clinicaltrials.gov

Share:
Add to list

Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults

Study ID: NCT04530565
Start Date: 2021-01-25
End Date: 2028-07-01
Study Type

Interventional

Study Phase

Phase3

No. of Participants

348

Intervention / Treatment

Biospecimen Collection

Blinatumomab

Bone Marrow Aspiration and Biopsy

Cyclophosphamide

Cytarabine

Underlined

Dexamethasone

Doxorubicin Hydrochloride

Echocardiography Test

Electrocardiography

Lumbar Puncture

Meat

Methotrexate

Multigated Acquisition Scan

Ponatinib Hydrochloride

Prednisone

Vincristine Sulfate

Sponsor

National Cancer Institute (NCI)

Source: clinicaltrials.gov

Share:
Add to list

TheraSphere With Durvalumab and Tremelimumab for HCC

Study ID: NCT05063565
Start Date: 2023-11-03
End Date: 2027-06
Study Type

Interventional

Study Phase

Phase2

No. of Participants

100

Intervention / Treatment

TheraSphere Y-90 glass microsphere therapy

Durvalumab (Imfinzi) immunotherapy

Tremelimumab immunotherapy

Sponsor

Boston Scientific Corporation

Source: clinicaltrials.gov

Share:
Add to list

Prospective Study of Sensation and Satisfaction in Cancer and Transgender Mastectomy Patients

Study ID: NCT06094257
Start Date: 2022-02-09
End Date: 2033-03
Study Type

Observational

Study Phase

Not Applicable

No. of Participants

400

Intervention / Treatment

Sensory testing

Sponsor

Weill Medical College of Cornell University

Source: clinicaltrials.gov

Share:
Add to list

First in Human Study of TORL-2-307-ADC in Participants With Advanced Cancer

Study ID: NCT05156866
Start Date: 2022-02-02
End Date: 2027-02-15
Study Type

Interventional

Study Phase

Phase1

No. of Participants

70

Intervention / Treatment

TORL-2-307-ADC

Sponsor

TORL Biotherapeutics, LLC

Source: clinicaltrials.gov

Share:
Add to list

Metabolomics and Genetic Diagnosing Pancreatic Neuroendocrine Tumors in MEN1 Patients

Study ID: NCT03048266
Start Date: 2015-11-05
End Date: 2026-11-01
Study Type

Observational

Study Phase

Not Applicable

No. of Participants

629

Intervention / Treatment
Sponsor

M.D. Anderson Cancer Center

Source: clinicaltrials.gov

Share:
Add to list

JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC

Study ID: NCT04892173
Start Date: 2022-01-27
End Date: 2027-12-31
Study Type

Interventional

Study Phase

Phase3

No. of Participants

500

Intervention / Treatment

JNJ-90301900 (NBTXR3)

Cetuximab

Radiation Therapy

Sponsor

Johnson & Johnson Enterprise Innovation Inc.

Source: clinicaltrials.gov

Share:
Add to list

Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers

Study ID: NCT04886531
Start Date: 2022-07-21
End Date: 2025-10
Study Type

Interventional

Study Phase

Phase2

No. of Participants

30

Intervention / Treatment

Neratinib

(L) or Anastrozole (A)

Trastuzumab

Sponsor

Ruth O'Regan

Source: clinicaltrials.gov

Share:
Add to list